Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Nike Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Nike Inc trades at $34.71 (market cap $51.60B). The key difference: Nike Inc is far larger — about 8.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Nike Inc pays a 4.72% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Nike Inc for 155 Days on average.
| IOVA | NKE | |
|---|---|---|
Market Cap | $6.04B | $51.60B |
Volume | 14,805,993 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $69.68 |
52-Week Low | $1.81 | $33.87 |
Typical Hold Time | 0 Days | 155 Days |
Enterprise Value | $5.97B | $54.30B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nike (NKE) trades at $34.74, up 1.11% with bearish technical signals despite recent earnings beats. The company faces revenue pressure with FY2025 sales declining to $46.31B and net margin compressing to 6.74%. Analyst consensus remains positive with a $36.98 price target, though technical indicators show 16 sell signals against 2 buy signals. Recent news highlights challenges in China and EMEA markets while emphasizing Nike's strong brand positioning.
Nike's investment case balances strong brand equity against near-term operational headwinds. The stock offers value at 16.62 P/E with 21.56% ROE, but investors face risks from sluggish consumer demand and margin pressure. The upcoming Q4 2026 earnings on June 30 will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
